{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:27:55Z","timestamp":1784366875098,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014914","name":"Deutscher Fondsverband","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ajoc.2024.102028","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T09:35:45Z","timestamp":1709199345000},"page":"102028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Erdafitinib-associated retinal alterations and rapid onset bilateral white cataracts"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9997-2947","authenticated-orcid":false,"given":"Antoine G.","family":"Sassine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz","family":"Cakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey","family":"Della Vecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6763-7768","authenticated-orcid":false,"given":"Justis P.","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajoc.2024.102028_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103091","article-title":"Prevention and treatment of FGFR inhibitor-associated toxicities","volume":"155","author":"Mahipal","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ajoc.2024.102028_bib2","unstructured":"FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. U.S. Food and Drug Administration. Published April 12, 2019. Accessed March 25, 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma."},{"issue":"4","key":"10.1016\/j.ajoc.2024.102028_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajoc.2024.102028_bib4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ajoc.2024.102028_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2474126417751724","article-title":"Reversible macular lesions in the setting of oral pan-fibroblast growth factor inhibitor for the treatment of bladder cancer","volume":"2","author":"Prensky","year":"2018","journal-title":"Journal of VitreoRetinal Diseases"},{"issue":"2","key":"10.1016\/j.ajoc.2024.102028_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2020.10.005","article-title":"Pseudovitelliform maculopathy associated with FGFR inhibitor therapy","volume":"5","author":"Ramtohul","year":"2021","journal-title":"Ophthalmology Retina"},{"issue":"1","key":"10.1016\/j.ajoc.2024.102028_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jfo.2020.03.018","article-title":"Reversible corneal stromal thinning, acute-onset white cataract and angle-closure glaucoma due to erdafitinib, a fibroblast growth factor receptor inhibitor: report of three cases","volume":"44","author":"Bauters","year":"2021","journal-title":"J Fr Ophtalmol"},{"issue":"6","key":"10.1016\/j.ajoc.2024.102028_bib8","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ctrv.2013.01.003","article-title":"Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities","volume":"39","author":"van der Noll","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.ajoc.2024.102028_bib9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.semcdb.2006.10.002","article-title":"An essential role for FGF receptor signaling in lens development","volume":"17","author":"Robinson","year":"2006","journal-title":"Semin Cell Dev Biol"},{"issue":"1568","key":"10.1016\/j.ajoc.2024.102028_bib10","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1098\/rstb.2010.0339","article-title":"Understanding the role of growth factors in embryonic development: insights from the lens","volume":"366","author":"Lovicu","year":"2011","journal-title":"Philos Trans R Soc Lond B Biol Sci"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993624000380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993624000380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T11:38:48Z","timestamp":1716291528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993624000380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":10,"alternative-id":["S2451993624000380"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2024.102028","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erdafitinib-associated retinal alterations and rapid onset bilateral white cataracts","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2024.102028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102028"}}